Lonza sells off specialty ingredients company to focus on drugs

Feb. 9, 2021

Lonza has agreed to sell its specialty ingredients company to Bain Capital and Cinven for $4.7 billion.

As part of the deal, the companies will acquire Lonza’s ingredients for anti-dandruff shampoo, hygiene products, nutritional supplements and more. 

The deal will allow Lonza, one of the world’s largest contract manufacturing companies, to focus its growth on “strategic priorities” such drug development and production. Lonza has been at the center of the COVID-19 production push by partnering with Moderna on its vaccine candidate and AstraZeneca on its antibody treatment.   

According to Reuters, revenue for Lonza’s specialty ingredients company fell by 2.1 percent last year, while its drug, biotech and nutrition revenues soared by 7.2 percent.

Read the Reuters report.